File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions

TitleA rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions
Authors
Koszalka, PaulinaFarrukee, RubaiyeaMifsud, EdinVijaykrishna, DhanasekaranHurt, Aeron C.
Keywordsbaloxavir marboxil
influenza viruses
pyrosequencing
I38T
antiviral resistance
Issue Date2020
Citation
Influenza and Other Respiratory Viruses, 2020, v. 14, n. 4, p. 460-464 How to Cite?
DOI: http://dx.doi.org/10.1111/irv.12725
Abstract© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making.
Persistent Identifierhttp://hdl.handle.net/10722/288791
ISSN
1750-2640
2023 Impact Factor: 4.3
2023 SCImago Journal Rankings: 1.485
PubMed Central ID
PMC7298287
ISI Accession Number ID
WOS:000512456200001

 

DC FieldValueLanguage
dc.contributor.authorKoszalka, Paulina-
dc.contributor.authorFarrukee, Rubaiyea-
dc.contributor.authorMifsud, Edin-
dc.contributor.authorVijaykrishna, Dhanasekaran-
dc.contributor.authorHurt, Aeron C.-
dc.date.accessioned2020-10-12T08:05:53Z-
dc.date.available2020-10-12T08:05:53Z-
dc.date.issued2020-
dc.identifier.citationInfluenza and Other Respiratory Viruses, 2020, v. 14, n. 4, p. 460-464-
dc.identifier.issn1750-2640-
dc.identifier.urihttp://hdl.handle.net/10722/288791-
dc.description.abstract© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making.-
dc.languageeng-
dc.relation.ispartofInfluenza and Other Respiratory Viruses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectbaloxavir marboxil-
dc.subjectinfluenza viruses-
dc.subjectpyrosequencing-
dc.subjectI38T-
dc.subjectantiviral resistance-
dc.titleA rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1111/irv.12725-
dc.identifier.pmid32045100-
dc.identifier.pmcidPMC7298287-
dc.identifier.scopuseid_2-s2.0-85079367050-
dc.identifier.hkuros317452-
dc.identifier.volume14-
dc.identifier.issue4-
dc.identifier.spage460-
dc.identifier.epage464-
dc.identifier.eissn1750-2659-
dc.identifier.isiWOS:000512456200001-
dc.identifier.issnl1750-2640-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats